Objective: To assess the efficacy and safety of Shenfu injection in preventing chemotherapy-induced peripheral neurotoxicity in cancer patients. Method: Randomized controlled trials (RCTs) for Shenfu injection in preventing CIPN efficacy were searched in PubMed

Embase

Cochrane Libraries

CNKI

WanFang Data

VIP database since the date of establishment to June 2015. Statistical analysis was performed with RevMan5.3. Result: Nine RCTs involving 1 047 patients were included. According to the results of Meta-analysis. ① The Shenfu group was more effective than the control group with a decreased overall incidence of CIPN [RR=0.53

95%CI(0.36

0.77)

P=0.000 8]and incidence of severe CIPN [RR=0.48

95%CI(0.31

0.74)

P=0.000 8]. ② There were no statistical significance in objective response rate between the two groups. The results of subgroup analysis showed that ① The Shenfu group was more effective than the control group with a decreased overall incidence of peripheral neurotoxicity [RR=0.59

95%CI(0.43

0.82)

P=0.001]and incidence of severe peripheral neurotoxicity induced by oxaliplatin [RR=0.45

95%CI(0.26

0.78)

P=0.005]. ② Shenfu injection had no effect on CIPN induced by other chemotherapy regimens (excluding oxaliplatin). Conclusion: Shenfu injection shows a significant advantage in preventing oxaliplatin-induced peripheral neurotoxicity (OIPN).